Ardent Health, Inc. (ARDT): what the price requires

The current priced-in claim for Ardent Health, Inc. (ARDT) is temporarily suppressed because the live engine record is unavailable. The dated report remains a snapshot, not a current market read.

Generated: 2026-07-19 · Source: https://boothcheck.com/report/ARDT

Headline

FieldValue
TickerARDT
CompanyArdent Health, Inc.
Current price$10.15/sh

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin needed1.2%
Operating margin today4.2%
Margin compression implied-3.0pp
Multiple paid12x operating income

The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.

The price sits below what even a 5%/yr operating-profit decline would warrant; the inversion reports a bound, not a solved growth path.

Solve inputs: computed at a 7% cost of capital with 4% terminal growth over a 5-year stage (computed at the 7% minimum rate; the CAPM rate 5.9% sits below it).

Reconcile: at the x-ray's 9.3% required return this reads ~0.4%/yr; the models below use their own rates.

How unusual the bet is: within-range (limited comparison data)

ReferenceValue
cohort percentile (of 113 peers)13
implied end-window share0%

Valuation X-Ray

The price is supported by asset-based and earnings-power and relative-multiple and growth-DCF value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset0.95x4justifies
Earnings0.99x3justifies
Relative0.52x2justifies
Growth0.38x3justifies

Families that justify the price: Asset, Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 6.9%); the inversion above states its own rate.

Per-Model Detail (n=12)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$113.800.09xyesFCF base $0.5B, growth 7% (input: historical growth), terminal g 4.0%, WACC 6.9%, 6yr projection
DCF Exit MultipleGrowth$26.640.38xyesExit EV/EBITDA: 43.1x / 45.1x / 47.1x (bear / base = today's held flat / bull), 6yr
Relative ValuationRelative$10.650.95xyesP/E 18x (static sector reference · 2026-04), scenarios: 15.0x / 18.0x / 21.0x (bear / base = reference held flat / bull), EV/EBITDA 21.94x
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$10.240.99xyesBV/sh $9.43, ROE (TTM) 10.0%, ke 9.3%
Two-Stage Excess ReturnAsset$10.660.95xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$8.201.24xyesRev $6.4B, growth 7% (input: historical growth; tapered), Terminal P/S: 0.2x / 0.2x / 0.3x (bear / base = today's held flat / bull, cap 8x)
Growth-Adjusted P/ERelative——no—
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings——no—
Residual IncomeAsset$10.730.95xyesBV $9.43 + 5yr PV of (ROE (TTM) 10.0% − Kₑ 9.3%) × BV; BV grows 6.5%/yr
Graham NumberAsset$14.200.71xyes√(22.5 × EPS $0.95 × BVPS $9.43) — Graham's conservative floor
EV/EBITDA RelativeRelative$0.1192.27xyesEBITDA $0.04B × sector EV/EBITDA 12.0x (excluded from median)
FCF YieldEarnings$29.640.34xyesFCF $435.1M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings$0.8012.69xyesEPS $0.95 × (8.5 + 2×-5.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative$113.370.09xyesRevenue $6.43B × sector P/S 2.5x
PEG Fair ValueRelative——no—
Earnings YieldEarnings$10.270.99xyesEPS $0.95 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net debt$530.8m
Net debt / NOPAT (after-tax)2.52x
Net debt / operating income (pre-tax)1.98x
Share count CAGR (dilution)4.3%
Burning cashno

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

Bull Case

The competitive position is the foundation of the bull case, and for a hospital operator that position is local. Ardent runs leading or near-leading hospital systems in mid-sized markets where it has scale that a new entrant cannot easily build, because a hospital network is expensive to replicate and embedded in its community's referral patterns and payer relationships. That density is what lets Ardent negotiate managed-care contracts from a position of strength, and the company entered 2026 with about 89% of its managed-care contracts signed at headline rates similar to the prior year. A regional hospital system with signed pricing and entrenched market share is a more defensible business than the thin reported margin suggests.

The operating trajectory is improving faster than the top line, which is the sign of a business gaining efficiency. First-quarter 2026 revenue grew 7.0% to $1.60 billion, but adjusted EBITDA grew far faster, up 26.3% to $124 million. Part of that is the company's IMPACT cost program, on track to deliver $55 million of savings in 2026, and part is mix, with surgeries up 1.2% even as admissions dipped on weather and a light respiratory season. Ardent also upgraded how it measures collectability; the 10-K notes it "implemented a new revenue accounting system that provided management with additional information to more precisely estimate the collectability of accounts receivable, particularly with respect to more timely consideration of payor denial and payment trends." Better visibility into denials is exactly where a hospital recovers margin.

The deleveraging adds a financial tailwind to the operating one. Lease-adjusted net leverage fell to 2.6 times from 3.0 times a year earlier, with about $610 million of cash and $0.9 billion of available liquidity. Management reaffirmed full-year guidance of $6.4 to $6.7 billion in revenue and $485 to $535 million in adjusted EBITDA. Against a healthcare-services cohort that includes Tenet, Pediatrix, and Surgery Partners, the bull case is that Ardent is a regionally entrenched operator with improving margins, falling leverage, and a price that values it below its demonstrated earnings power.

Bear Case

The bear case is a balance-sheet-and-reimbursement argument, and reimbursement is the part a hospital operator cannot control. Ardent's revenue depends on what commercial insurers, Medicare, and Medicaid agree to pay, and the policy backdrop carries real risk: Medicaid supplemental-payment uncertainty is a live concern, and payer denial trends pressure collections directly. The 10-K's own disclosures center on the difficulty of estimating what gets collected, describing the work of more "timely consideration of payor denial and payment trends" to gauge collectability. A 7% revenue gain means little if a larger share of it is denied, delayed, or repriced by a payer, and a hospital earning a 4.2% operating margin has almost no cushion to absorb an adverse reimbursement change.

The mix shift in the quarter is an early warning the bull case should not wave away. Admissions declined 1.1%, and while surgeries grew, the commentary noted that core commercial admissions excluding the exchanges were slightly weaker while Medicare rose as a percent of revenue. Commercial volume is the most profitable, and a drift toward government payers, who reimburse less, pressures the margin even when total volume holds. Hospitals are operationally leveraged: a small shift in payer mix or volume moves the thin margin a lot, and the bear's concern is that the favorable EBITDA growth this quarter leaned on cost cuts that do not repeat indefinitely.

On the balance sheet, leverage is improving but not negligible. Net debt of about $531 million is roughly two times trailing operating income on a corporate basis, and the lease-adjusted figure of 2.6 times reflects the substantial lease obligations a hospital operator carries. The share count has grown about 4.3% a year, a function of the company's relatively recent public listing. The valuation honestly reads as cheap rather than expensive, with every method supporting the price, so this is not an overvaluation bear. It is a structural bear: a hospital operator is a regulated, reimbursement-dependent, operationally leveraged business, and the low multiple is the market pricing the genuine risk that Medicaid policy, payer denials, or a payer-mix shift compresses an already-thin margin. The price is low for reasons, and the bear's question is whether those reasons resolve favorably.

Valuation

Ardent's price is a value read, not a growth bet, and the inversion makes the point bluntly: at about 11 times operating income, the price sits below what even a 5%-a-year decline in operating profit would warrant. That is the framework's way of saying the market has priced a shrinking business, while the company just grew revenue 7% and EBITDA 26%. The honest framing is a bound rather than a solved growth rate: the price requires so little of the business that the question is not whether Ardent can grow into the multiple, but why the market is discounting it so heavily, which points straight to reimbursement and policy risk rather than to operating weakness.

The methods agree the price is cheap, and they agree to an unusual degree. Every family of valuation method supports or sits above the price: asset value, earnings power, peer multiples, and forward growth all land above where the stock trades. When all four families say cheap, the disagreement is between the methods, which value the hospitals' assets and cash flow, and the market, which is applying a discount for the regulated, reimbursement-dependent nature of the business. There is no premium to explain here, only a discount to judge, and the valuation question is whether that discount is the market being prudent about Medicaid and payer risk or being too pessimistic about an operator that is growing EBITDA and cutting leverage.

Solvency is adequate and improving, which bounds the downside. Net debt of about $531 million is roughly two times operating income, lease-adjusted leverage fell to 2.6 times from 3.0 times, and the company holds about $610 million of cash against $0.9 billion of liquidity. That is not a stressed balance sheet, so the downside is not a solvency event; it is margin compression from reimbursement. For a hospital, the right frame is operating leverage and payer mix rather than the coverage math of an industrial, and the thin margin means small reimbursement changes matter a lot. Against the healthcare-services cohort, Ardent is priced at the value end, and the price reflects the market's discount for policy and payer risk on a regionally entrenched operator whose own numbers are moving the right way.

Catalysts

The first-quarter 2026 report paired solid revenue and EBITDA growth with an EPS miss. Total revenue rose 7.0% to $1.60 billion, adjusted EBITDA grew 26.3% to $124 million, and net income attributable to Ardent was $40 million, though earnings fell short of the EPS forecast. Operationally, surgeries grew 1.2% while admissions declined 1.1% on severe weather and a lighter respiratory season, with Medicare rising as a percent of revenue.

Guidance and cost initiatives were the constructive signals. Management reaffirmed full-year 2026 guidance of $6.4 to $6.7 billion in revenue and $485 to $535 million in adjusted EBITDA, and the IMPACT cost program is on track for $55 million of savings in 2026. The company also reported lease-adjusted net leverage down to 2.6 times and about 89% of 2026 managed-care contracts signed at rates similar to last year.

The forward watch items are reimbursement policy and payer mix. Medicaid supplemental-payment uncertainty and the trajectory of payer denials are the external variables with the most leverage on the margin, and management's continued work to strengthen denial and underpayment terms is the operational lever to track. On volume, whether commercial admissions stabilize after a weather-affected quarter determines how much the favorable mix supports margins, and continued progress on the IMPACT savings and leverage reduction would reinforce the value case the low multiple reflects.

Peer Cohorts (Per Segment, With Filing Citations)

Healthcare Services (single segment) (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Ardent Health Q1 2026 results, 2026

View the full interactive ARDT report on boothcheck